NovaDel Pharma Announces That Ondansetron Oral Spray Has Met The Key Regulatory Requirement Of Bioequivalence; NovaDel’s Partner, Hana Biosciences, Inc., Has Completed Its Clinical Program To Support A 505(b)(2) NDA Submission In 2006

NovaDel Pharma Inc. (AMEX: NVD) today announced that Hana Bioscienses, NovaDel’s partner in the development and commercialization of Zensana(TM) (ondansetron oral spray), has successfully completed all clinical trials required for FDA registration under section 505(b)(2).